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Abstract 
Background Heightened sympathetic nerve activity is associated with occurrence 
of ventricular arrhythmia (VA). 
Objective To investigate the association of skin sympathetic nerve activity (SKNA) 
and VA occurrence. 
Methods We prospectively enrolled 65 patients with severe cardiomyopathy. Of 
these, 39 had recent sustained VA episodes (VA-1 group), 11 had intractable VA 
undergoing sedation with general anesthesia (VA-2 group), and 15 had no known 
history of VA (VA-Ctrl group). All patients had simultaneous SKNA and ECG 
recording. SKNA was assessed using an average value (aSKNA), a variable value 
(vSKNA), and the number of bursts of SKNA (bSKNA). 
Results   VA-1 group had higher aSKNA and vSKNA compared with the VA-Ctrl 
group (aSKNA: 1.41±0.53 vs 0.98±0.41 µV, P=.003; vSKNA: 0.52±0.22 vs 
0.30±0.16 µV, P<.001) and the VA-2 group (aSKNA: 0.83±0.22 µV, P<.001; 
vSKNA: 0.23±0.11 µV; P<.001). Although the VA-2 group had more VA episodes 
than VA-1 group (median, 5 vs 2; P=.01), their SKNA was the lowest among the 3 
groups. Multivariate Cox regression analysis showed that a higher aSKNA at 
baseline was an independent predictor of lower VA recurrence rate during a 
417±279-day follow-up (hazard ratio, 0.325; 95% CI, 0.119-0.883; P=.03). 
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A >15% reduction in aSKNA after therapy was associated with a lower subsequent 
VA event rate (hazard ratio, 0.222; 95% CI, 0.057-0.864; P=.03). 
Conclusions Patients with VA had increased SKNA as compared with control. 
Both SKNA and sustained VA could be suppressed by general anesthesia. The 
aSKNA at baseline was an independent predictor of VA recurrence.  
 
Key words: autonomic nervous system; sedation; skin sympathetic nerve activity; 
sympathetic tone; ventricular arrhythmia, 
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Introduction 
The autonomic nervous system has an important role in the genesis of cardiac 
arrhythmias.1, 2Sympathetic nerve activity can be recorded by using 
microneurography techniques, but this approach is invasive and requires technical 
expertise. Doytchinova et al3 recently developed a method that uses conventional 
ECG patch electrodes to noninvasively record skin sympathetic nerve activity 
(SKNA) simultaneously with electrocardiography (ECG). This new method 
(neuECG) was used in human studies to show an association between increased 
SKNA and the onset and termination of paroxysmal atrial fibrillation,4 premature 
atrial and ventricular contractions,5 and ventricular tachyarrhythmia.3, 6The 
noninvasive estimation of sympathetic tone may provide new insights into the 
mechanisms of cardiac arrhythmias and associated risk factors. It may also provide 
a measure of the autonomic response to any therapies for arrhythmogenesis. Here, 
we aimed to study neuECG in patients with cardiomyopathy and sustained 
ventricular arrhythmia (VA), including ventricular tachycardia and fibrillation. We 
hypothesized that increased SKNA was associated with ventricular 
arrhythmogenesis and that the reduced SKNA was predictive of VA recurrence. 
 
Methods 
Study Population 
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We prospectively enrolled 65 patients with structural heart disease and ischemic or 
nonischemic cardiomyopathy between March 2015 and October 2018, at the Mayo 
Clinic, Rochester, MN. Subjects at risk of VA were categorized into 3 groups. The 
VA-1 group consisted of 39 patients with recurrent VA requiring implantable 
cardioverter-defibrillator (ICD) therapies, and SKNA was recorded while patients 
were awake. The VA-2 group consisted of 11 patients with recurrent VA requiring 
ICD therapies who underwent deep sedation with general anesthesia (GA) with 
intravenous propofol or dexmedetomidine for VA control. The level of sedation 
was assessed with the Richmond Agitation Sedation Scale (optimal score, −3 or 
−4). The airway was protected by intubation and ventilation, and SKNA was 
recorded during sedation with GA. As sedation may impact on the sympathetic 
activity and VA control, we separated this group (VA-2) from those who did not 
have sedation (VA-1) for analysis. The VA-Ctrl group consisted of 15 patients 
without a history of VA who received an ICD for primary prevention of sudden 
cardiac death. 
       Data from all VA episodes (including sustained episodes) that occurred before 
and during the hospitalization were collected by ICD interrogation and telemetry 
monitoring. A VA storm was defined as 3 or more sustained episodes of VA, or 
separate appropriate ICD therapies over a 24-hour period.7 The study protocol was 
approved by the Institutional Review Boards of Mayo Clinic (Rochester, MN). All 
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patients have given written informed consent to participate the study. 
 
SKNA Data Acquisition   
We used a modified portable ME6000 Biomonitor (Mega Electronics Ltd) for data 
acquisition. All patients were monitored with ECG leads I and II, with electrodes 
placed in the right, left subclavian areas and left lower abdomen; another channel 
was used to record SKNA from the left arm. Data were obtained continuously for 
30 to 60 minutes and digitized at 10,000/s. We analyzed recordings from all 
channels using custom-written software, as described previously.5 The neuECG 
signals were amplified and passed through a bandpass filter (30-150 Hz) to display 
the ECG. The same neuECG signals were passed through another bandpass filter 
(500-1,000 Hz) to display SKNA.  
For quantitative analyses, we reviewed all digitized SKNA signals during a 
time window and divided the total voltage by the number of digitized samples in 
the window to obtain the average voltage of SKNA per sample. Neurograms from 
every 100-millisecond window were rectified and displayed over time to simulate 
the display methods of microneurography.3 Data segments with poor signal quality 
or numerous artifacts were excluded from the analyses. Two investigators 
independently reviewed the recordings. When discrepancies were identified, the 
reviewers repeated the data review process together to ascertain the findings. 
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SKNA Assessment  
SKNA was assessed by considering the average voltage of SKNA (aSKNA), a 
variable value of SKNA (vSKNA), and the number of bursts of SKNA (bSKNA).  
The aSKNA represents an overall average voltage of SKNA and was obtained by 
calculating the average value of the continuous monitoring window (60-second 
window), The bursts of enhanced SKNA (bSKNA) may be transient, in association 
with temporal clustering VA. bSKNA is quantified by determining the number of 
enhanced nerve bursts within the first 10 minutes of SKNA data (every 10-second 
window). The variation of SKNA (vSKNA) may reflect the changes in 
sympathetic tone and was defined as the standard deviation of aSKNA in every 60-
second window.  As Kusayama et al8 described recently, we plotted the proportion 
of amplitude distribution of SKNA to detect two or more Gaussian distributions. 
The mean plus 3 times the standard deviation of the first Gaussian distribution was 
used as the threshold. The nerve activity amplitudes that exceed the threshold were 
deemed to be in the burst.  
 
Follow-up and Outcomes 
Patients were asked to return for a follow-up SKNA assessment at 3 months after 
hospital discharge. aSKNA was defined as reduced if the voltage was at least 15% 
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lower than the baseline value. ICD was interrogated to identify any episodes of 
recurrent sustained VA. The primary end point was recurrent sustained VA 
requiring ICD therapy (including antitachycardia pacing and shock). 
 
Statistical Analysis 
Continuous variables are expressed as mean ± SD. One-way analysis of variance 
was used to compare the 3 patient groups. Categorical variables are presented as 
counts and percentages, and groups were compared by using the χ2 or Fisher exact 
test, as appropriate. Kaplan-Meier survival curves were generated, and the log-rank 
test was used to assess differences between curves. In addition, hazard ratios with 
95% CIs and P values from Cox regression analyses were introduced to identify 
risk factors of VA recurrence. Two-sided P values less than.05 were considered 
significant. All statistical analyses were performed by using SPSS v.23 (IBM 
Corporation). 
 
Results 
Patient Characteristics 
Fifty patients were admitted for VA with appropriate ICD therapies; 39 were in the 
VA-1 group (13 [33%] with VA storm) and 11 were in the VA-2 group (9 [82%] 
with VA storm). Fifteen patients without VA were enrolled in the VA-Ctrl group. 
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The mean ± SD age was 64.0±13.1 years; 52 patients (80%) were men. Table 1 
shows patient baseline characteristics, stratified by VA group. 
 
Ventricular Arrhythmia 
Patients in the VA-1 group had a median (range) of 2 (1-112) episodes of sustained 
VA within 7 days before admission, whereas patients in the VA-2 group had a 
median (range) of 5 (2-124) episodes (P=.01). The median (range) time from last 
episode of VA to SKNA recording was 2 (1-7) days in VA-1 group, and 1 (1-2) 
day in VA-2 group (P<.001). Of the 39 patients in the VA-1 group, VA was 
controlled after receiving antiarrhythmic drugs (AADs, n=38), undergoing catheter 
ablation (n=17, median time from ablation to SKNA recording 1 (range 1-4) day), 
or receiving stellate ganglion block (SGB, n=2) following SKNA recording. One 
patient died of VA and 1 died of cardiogenic shock during hospitalization. Of the 
11 patients in VA-2 group, 9 had VA storm, despite receiving AADs. The VA was 
controlled by sedation with GA (n=11), catheter ablation (n=8, media time from 
ablation to SKNA recording 1 (range1-7) day, and SGB (n=5, median time to 
SKNA recording 1(range 1-7) day. Similar to the VA-1 group, 1 patient died of 
VA and 1 died of cardiogenic shock during hospitalization. 
 
Skin Sympathetic Nerve Activity 
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The mean±SD neuECG recording time was 50±16 minutes. The aSKNA was 
higher for the VA-1 group than the VA-2 group (mean±SD, 1.41±0.53 vs 
0.83±0.22 µV; P<.001) and VA-Ctrl group (0.98±0.41 µV; P=.003) (Figure 1A). 
The vSKNA was substantially higher in the VA-1 group compared with the VA-2 
group (0.52±0.22 vs 0.23±0.11 µV; P<.001) and the VA-Ctrl group (0.30±0.16 µV; 
P<.001) (Figure 1B). The bSKNA was higher for the VA-1 group than the VA-2 
group (18.30±10.82 vs 7.91±7.06; P=.004), whereas the difference between the 
VA-1 group and VA-Ctrl group was not significant (Figure 1C). Figure 2 shows 
representative of SKNA tracings from the 3 groups. A patient in the VA-1 group 
presented with high-amplitude SKNA and a prolonged burst of activity (Figure 
2A), whereas a patient with VA storm in the VA-2 group had lower-amplitude 
SKNA and a short burst of activity (Figure 2B). A patient in the VA-Ctrl group 
had intermediate-amplitude SKNA (Figure 2C). Within the VA-1 group, the 13 
patients with VA storms (33.3%) had a higher vSKNA than those without VA 
storms (0.61±0.20 vs 0.47±0.21 µV; P=.04). 
In the VA-2 group, patients did not have recurrence of sustained VA during 
sedation with GA. Figure 3A depicts crescendo bursts of SKNA preceding the 
episodes of nonsustained VA while the patient was awake (patient with VA storms, 
VA-2 group). After sedation with GA and AAD therapy, VA and SKNA were 
suppressed simultaneously (Figure 3B). The average amplitude of SKNA was 
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reduced by 60%. 
 
Predictors of VA Recurrence 
A multivariate Cox regression analysis of potential risk factors in the VA-1 group 
showed that a higher aSKNA  at baseline was the only independent predictor of 
lower VA recurrence rate during a mean follow-up of 417±279 days (hazard ratio, 
0.325; 95% CI, 0.119-0.883; P=.03;adjusted for age) (Table 2). The VT-2 group 
was not included in this analysis because SKNA recordings were obtained during 
sedation with GA. At the 3-month follow-up, 19 patients underwent a repeat 
SKNA recording. Of these, 11 (57.9%) had recurrent VA during a mean follow-up 
of 468±268 days. A >15% reduction in aSKNA at 3-month follow-up was 
associated with a lower subsequent VA event rate compared with those who did not 
meet this threshold (hazard ratio, 0.222; 95% CI, 0.057-0.864; P=.03) (Figure 4). 
VA occurred in only 1 patient with nonischemic cardiomyopathy during follow-up 
in the control group. 
 
Discussion 
This study aimed to determine the association of SKNA with sustained VA events 
in patients with cardiomyopathy. We had several notable findings: 1) patients with 
VA had increased aSKNA, vSKNA, and bSKNA; 2) sedation with GA markedly 
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suppressed VA events and SKNA, and 3) a higher aSKNA at baseline and greater 
SKNA suppression at the 3-month follow-up were associated with a lower 
incidence of long-term recurrence rate for VA. Peripheral sympathetic nerve 
activity can be directly measured with microneurography, 9, 10 but 
microneurography requires an invasive approach and technical expertise. 4, 5 Our 
study showed the feasibility of noninvasively measuring SKNA by placing 
recording patches on the chest and arm and collecting data with the readily 
available ME6000 device. This approach may be a more convenient method for 
assessing sympathetic activity than microneurography.  
 
Noninvasive Measurement of Sympathetic Nerve Activity in Patients with VA 
The autonomic nervous system regulates cardiac ion channel and myocardial 
contractility. Elevated sympathetic activity is potentially responsible for initiating 
VA in patients with or without heart failure.11 Left stellate ganglion nerve activity 
(SGNA) dominates cardiac sympathetic control and increases sympathetic output 
before the onset of VA, and animal models and human studies have shown that 
inhibition of left stellate ganglion activity reduces the incidence of VA.12-14 Axonal 
tracer studies have shown that a considerable portion of skin sympathetic nerves in 
the neck and upper thorax originate from the ipsilateral stellate ganglion.15, 16 
Subcutaneous nerve activity and superficial SKNA closely correlate with SGNA in 
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ambulatory canine models.10, 17, 18 When SKNA and left SGNA were 
simultaneously recorded continuously in ambulatory canine models, there was a 
positive correlation between SKNA and SGNA and between SKNA and heart rate, 
suggesting the SKNA can be used to estimate SGNA.10 
     The findings of elevated aSKNA, vSKNA, and bSKNA in our patients who 
were hospitalized for recurrent VA events (compared with those who had no 
known VA documented by ICD) support a model in which VA is associated with 
heightened sympathetic activity. The periodic crescendo skin nerve bursts that 
preceded VA episodes in canine models 12 were also observed in patients with VA 
in our study (when VA episodes were captured). 
 
Sympathetic Suppression and SKNA 
VA episodes are associated with various triggers, insults, and underlying severe 
cardiomyopathy,and incessant, recurrent VA constitutes a medical emergency. 
Often, medical therapy and catheter ablation fail to control this malignant 
arrhythmia, and hemodynamic stability is not achieved. A recent study reported 
that large and sustained sympathetic nerve activity was associated with the 
temporal clustering of VA episodes, suggesting that neuromodulation methods that 
inhibit or reduce sympathetic nerve activity may prevent arrhythmia clustering. 8 
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Sedation with GA mitigates intractable VA.19 One of the drug used is 
dexmedetomidine, which acts in the central nervous system to augment α2 
adrenoreceptor restraint on sympathetic nerve activity to multiple tissues and 
vascular beds. Because of its potent sympatholytic action, dexmedetomidine 
administration is expected to significantly suppress the sympathetic nerve 
activity.20 A previous study used microneurography techniques to show that 
cocaine increases while dexmedetomidine decreases the skin sympathetic nerve 
activity, blood pressure and heart rate.21  In our patients with VA storms, GA plus 
other concomitant therapies effectively controlled incessant arrhythmia.  We 
observed the measured aSKNA, vSKNA, and bSKNA were lower in the VT-2 
group compared with the VT-1 group. This finding is novel because it shows 
evidence of suppression of sympathetic output by optimal sedation. Although a 
consensus has not been reached about the optimal level of sedation for treating VA 
storm, in patients with VA storm associated with hemodynamic instability, 
sedation with GA and invasive hemodynamic support may be indicated. Others 
have reported that propofol might be “antiarrhythmic,” considering its direct 
effects on the autonomic nervous system.22 Notably, 1 of our study patients had 
SKNA assessment during VA storms in the presedation and postsedation stages. 
GA markedly suppressed aSKNA, vSKNA, and bSKNA and simultaneously 
mitigated VA (Figure 2).This finding suggests that SKNA may mirror sympathetic 
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nerve activity in patients with VA and the SKNA recording may provide a feasible 
measurement when considering stellate ganglion block for VA control. 
 
Implications and Perspective 
In this prospective observational study, nearly half the patients had recurrent VA. 
We noted that patients with a higher aSKNA at baseline and greater reduction of 
aSKNA at 3-month follow-up were less likely to have subsequent VA episodes. 
This finding suggests a variation of sympathetic activity in individual patient. The 
elevated sympathetic output could be arrhythmogenic, associated with VA events 
and can be reduced by enhanced management of sympathetic control, such as 
sedation, β-blockers or SGB with a lower likelihood of VA recurrence. On the 
other hand, a lower sympathetic activity at baseline may suggest a more ventricular 
substrate-driven, less sympathetic participation in VA occurrence. These findings 
suggest that sympathetic nerve activity measurement might be used for long term 
arrhythmic risk assessment in patients with substrates of ventricular arrhythmia. 
 
Study Limitations 
Many factors such as age, body mass index, end-stage heart failure, and medication 
may affect SKNA. We also did not directly record the stellate ganglion nerve 
activity and correlate it with SKNA. As stated by Shelton et al,23 the signals of 
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SKNA may come from multiple sources, although some noise can be effectively 
filtered with conventional filters. The study was not able to assess the extent of 
sympathetic activation as we did not measure MSNA or heart rate variability. In 
addition, this is a prospective observational study. The VA patient grouping 
without or with sedation was upon physician’s discretion with potential patient 
selection bias. SKNA measures were obtained after sedation for most patients in 
VA-2 group because of the urgency of VA storm. Therefore, we do not have 
baseline SKNA measurements for comparison. 
 
Conclusion 
SKNA can be feasibly recorded noninvasively. SKNA and VA could be 
suppressed simultaneously by general anesthesia. Patients with higher SKNA at 
baseline and reduced SKNA after therapy implies involvement of high sympathetic 
tone and may have lower recurrence of VA, especially in patients with VA storms. 
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Figure Legends 
Figure 1. Comparison of aSKNA, vSKNA, and bSKNA, Stratified by VA 
Group.  
Patients in the VA-1 group had the highest aSKNA, vSKNA, and bSKNA, whereas 
patients in the VA-2 group had the lowest aSKNA (A), vSKNA (B), and bSKNA 
(C).  
aSKNA=average value of SKNA; SKNA=skin sympathetic nerve activity; 
vSKNA=variable value of SKNA; bSKNA=the number of burst of SKNA; 
VA=ventricular arrhythmia.  
Figure 2. Pattern of SKNA in VA-1, VA-2, and VA-Control Groups.  
SKNA was characterized by a large and sustained burst in the VA-1 group (A), 
whereas it was characterized by brief and sporadic bursts in the VA-2 group (B) 
and VA-Ctrl group (C).  
aSKNA=average value of SKNA; ECG=electrocardiogram; SKNA=skin 
sympathetic nerve activity; VA=ventricular arrhythmia.  
Figure 3. SKNA and VA Episodes Suppressed by Sedation.  
A, Bursts of SKNA (black arrows) preceded the onset of VA episodes (red arrows) 
before sedation (aSKNA=1.50 µV). B, SKNA and VA episodes were significantly 
suppressed simultaneously after sedation (aSKNA=0.61 µV). The heart rate 
decreased from 60 to 50 bpm (blue lines).  
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aSKNA=average value of SKNA; bpm=beats per minute; ECG=electrocardiogram; 
HR=heart rate; SKNA=skin sympathetic nerve activity; VA=ventricular 
arrhythmia.  
Figure 4. Repeat aSKNA and VA Recurrence.  
Kaplan-Meier curves showed that fewer patients had recurrent sustained VA if 
they had a >15% reduction in aSKNA compared with those with unreduced 
aSKNA.  
aSKNA=average value of SKNA; SKNA=skin sympathetic nerve activity; 
VA=ventricular arrhythmia 
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Table 1 Patients Characteristics 
Characteristic VA-1  
(n=39) 
VA-2  
(n=11) 
VA-Ctrl  
(n=15) 
P 
Value 
Age, (y) 66.1±10.2 58.5±16.2 62.7±16.7 .22 
Male, n (%) 35 (89.7) 8 (72.7) 9 (60) * .03 
Body mass index, (kg/m2) 32.6±5.6 31.3±5.5 27.4±5.1† .01 
Heart rate, (beats/min) 64.8±9.2 64.5±12.7 67.5±13.0 .58 
LVEF, (%) 30.0±10.9 34.3±11.5 26.2±7.8 .15 
LVIDd, (mm) 64.5±10.0 58.9±5.2 65.2±8.9 .16 
Ischemic heart disease, n 
(%) 
19 (48.7) 6 (54.5) 8 (53.3)     1.0 
Diabetes mellitus, n (%) 12 (30.8) 2 (18.2) 4 (26.7) .86 
Hypertension, n (%) 25 (64.1) 3 (27.3) 8 (53.3) .09 
Atrial fibrillation, n (%) 17 (43.6) 3 (27.3) 5 (33.3) .63 
Cardiac 
resynchronization 
therapy, n (%) 
22 (56.4) 3 (27.3) 3 (20.0) ‡ .04 
Sustained VA episodes, 
median (range ,n) 
2 (1-112) 5 (2-124) … .01 
VA storm, n (%) 13 (33.3) 9 (81.8) … .006 
AAD, n (%) 32 (82.1) 10 (90.9) … 1.0 
      Amiodarone 29 (74.4 ) 7(63.6) … 0.75 
      Mexiletine 8 (20.5 ) 6 (54.5) … 0.07 
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   Lidocaine 4 （?10.3（? 4 （?36.4（? … 0.10 
ß-blocker, n (%) 35 (89.7) 9 (81.8) 15 (100) .33 
Digoxin, n (%) 3 (7.7) 0 (0) 2 (13.3) .67 
ACEI/ARB, n (%) 30 (76.9) 7 (63.6) 13 (86.7) .39 
Diuretic, n (%) 25 (64.1) 4 (36.4) 10 (66.7) .26 
Aldactone, n (%) 10 (25.6) 5 (45.5) 6 (40.0) .34 
 
* VA-1 group vs VA-Ctrl group, P=.02. 
† VA-2 group vs VA-Ctrl group, P=.002. 
‡  VA-1 group vs VA-Ctrl group, P=.03. 
AAD=antiarrhythmic drug, including class I and class III agents; ACEI/ARB=angiotensin-
converting enzyme inhibitor/angiotensin II receptor blockers; Ctrl=control; LVEF=left 
ventricular ejection fraction; LVIDd=left ventricular internal diameter end diastole, 
VA=ventricular arrhythmia. 
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Table 2 Predictors of VA Recurrence in VA-1 Group  
 VA 
Recurrence  
(n=18) 
No VA  
(n=21) 
Univariate Analysis 
Hazard Ratio 
(95% CI) 
P 
Value 
Age, (y) 62.4±10.4 69.2±9.1 0.958 (0.916-1.001) .06 
Male, n (%) 18 (100) 17 (81.0) 0.191 (0.010-3.576) .27 
Body mass index, (kg/m2) 33.6±4.2 31.8±6.5 1.040 (0.959-1.127) .35 
Heart rate, (beats/min) 64.0±8.6 64.6±7.6 0.993 (0.932-1.058) .83 
LVEF, % 29.1±12.0 30.7±10.1 0.984 (0.939-1.031) .50 
LVEDd, (mm) 64.5±9.3 64.6±10.7 1.015 (0.963-1.064) .63 
Ischemic heart disease ,n (%) 7 (38.9) 12 (57.1) 1.889 (0.696-5.123) .21 
Diabetes mellitus, n (%) 7 (38.9) 5 (23.8) 1.531 (0.593-3.952) .38 
Hypertension, n (%) 12 (66.7) 13 (61.9) 0.947 (0.349-2.573) .92 
Atrial fibrillation, n (%) 9 (50.0) 8 (38.1) 2.082 (0.772-5.617) .15 
Cardiac resynchronization 
therapy, n (%) 
8 (44.4) 14 (66.7) 0.871 (0.339-2.236) .77 
Chronic kidney disease, n (%) 3 (16.7) 8 (38.1) 0.501 (0.144-1.738) .28 
VA storm, n (%) 8 (44.4) 5 (23.8) 0.560 (0.217-1.441) .23 
Ablation, n (%) 7 (38.9) 10 (47.6) 1.132 (0.702-1.824) .61 
AAD, n (%) 15 (83.3) 17 (81.0) 1.022 (0.293-3.561) .97 
ß-blocker, n (%) 16 (88.9) 19 (90.5) 0.700 (0.158-3.099) .64 
Digoxin, n (%) 2 (11.1) 1 (4.8) 1.554 (0.352-6.852) .56 
ACEI/ARB, n (%) 14 (77.8) 16 (76.2) 0.778 (0.250-2.421) .67 
Diuretic, n (%) 11 (61.1) 14 (66.7) 1.163 (0.441-3.066) .76 
Aldactone, n (%) 4 (22.2) 6 (28.6) 0.640 (0.209-1.957) .43 
aSKNA, (µV) 1.22±0.47 1.62±0.53 0.293 (0.109-0.785) .02 
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vSKNA, (µV) 0.46±0.23 0.56±0.19 0.998 (0.996-1.000) .09 
bSKNA, (n) 17.9±11.7 17.5±11.4 0.983 (0.937-1.031) .49 
AADs=antiarrhythmic drugs, including class I and class III agents; ACEI/ARB=angiotensin-converting enzyme 
inhibitor/angiotensin II receptor blockers; LVEF=left ventricular ejection fraction; LVEDD=left ventricular end 
diastolic diameter; VA=ventricular arrhythmia. 
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